Rituxan hits endpoints in late-stage skin disease trial
The drug demonstrated superiority to current standard-of-care to CellCept.
Read More
Tag: pemphigus vulgaris
US widens scope of Rituxan to include life-threatening skin condition
Roche group Genentech has received US approval for Rituxan to treat moderate to severe pemphigus vulgaris (PV), giving patients access to the first new therapy for the condition in more than 60 years.
Read More
- Kahimmune Therapeutics enters licensing agreement with Gustave Roussy and SATT Paris-Saclay
- IBSA UK&I launches Perovial for the treatment of acute Peyronie’s disease
- En Carta Diagnostics’ EC Pocket Lyme test receives FDA Breakthrough Device Designation
- ALK’s EURneffy receives positive CHMP opinion for emergency anaphylaxis treatment in children
- CERo reports encouraging early data from phase 1 trial of CER‑1236
